Fayong Luo, MD, PhD
Lab: MSB 6.034
Research: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease responsible for up to 30,000 deaths per year in the U.S. Despite decades of research, the pathogenesis of IPF is still not fully understood and there is no FDA approved treatment available. My research focuses on investigating the potential role of adenosine signaling pathways in IPF and other lung diseases with chronic injuries. By intratracheal or intraperitoneal injection of bleomycin, mouse lung fibrosis models are established. Mouse and rat lung epithelial cells are also used for in vitro study of adenosine signaling pathways. Extracellular adenosine levels are critical in acute or chronic lung injuries and are controlled by equilibrative nucleoside transporter (ENT) proteins. ENT protein expression can be further regulated in direct or indirect ways by hypoxia inducible factor-1α (hif-1 α) and transforming growth factor β (TGF-β), which are important molecules that play crucial rules in lung fibrosis. By investigating the potential networks among TGF-β, ENTs and adenosine, we will be able to better understand the pathogenesis of lung fibrosis, and therefore, generate novel drugs or therapeutic strategies for IPF.